Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    CAS  Article  Google Scholar 

  2. 2

    Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.

    CAS  Article  Google Scholar 

  3. 3

    Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA . Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169–3175.

    CAS  Article  Google Scholar 

  4. 4

    Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013; 121: 1824–1838.

    CAS  Article  Google Scholar 

  5. 5

    Casetti L, Martin-Lanneree S, Najjar I, Plo I, Auge S, Roy L et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res 2013; 73: 2052–2058.

    CAS  Article  Google Scholar 

  6. 6

    Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG . BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 2011; 4: 6.

    CAS  Article  Google Scholar 

  7. 7

    Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.

    CAS  Article  Google Scholar 

  8. 8

    Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396–409.

    CAS  Article  Google Scholar 

Download references


PG and MWD received grant support from LLS Screen-to-Lead and MWD received research funding from Bristol-Myers Squibb, Novartis, Celgene, Genzyme and Gilead. The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cell Biology at Rhode Island Hospital.

Author information



Corresponding author

Correspondence to M W Deininger.

Ethics declarations

Competing interests

MWD served as a paid advisory board member and consultant for Bristol-Myers Squibb, ARIAD Pharmaceuticals Inc., Novartis, Incyte Corporation and Pfizer. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eiring, A., Kraft, I., Page, B. et al. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leukemia Suppl 3, S5–S6 (2014).

Download citation


  • TKI resistance
  • BCR-ABL1-independent resistance
  • BCR-ABL1-dependent resistance
  • CML stem cell
  • STAT3
  • pSTAT3Y705
  • BP-5-087

Further reading


Quick links